Huntington National Bank Has $21.43 Million Position in Pfizer Inc. (NYSE:PFE)

Huntington National Bank lessened its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 3.0% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 740,355 shares of the biopharmaceutical company's stock after selling 22,520 shares during the period. Huntington National Bank's holdings in Pfizer were worth $21,426,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Summit Asset Management LLC grew its stake in Pfizer by 5.0% during the 3rd quarter. Summit Asset Management LLC now owns 22,428 shares of the biopharmaceutical company's stock valued at $649,000 after acquiring an additional 1,063 shares in the last quarter. Plato Investment Management Ltd grew its position in Pfizer by 11.5% during the third quarter. Plato Investment Management Ltd now owns 158,445 shares of the biopharmaceutical company's stock valued at $4,581,000 after purchasing an additional 16,327 shares in the last quarter. Schrum Private Wealth Management LLC lifted its position in Pfizer by 51.6% in the 3rd quarter. Schrum Private Wealth Management LLC now owns 31,302 shares of the biopharmaceutical company's stock worth $906,000 after buying an additional 10,658 shares in the last quarter. ICICI Prudential Asset Management Co Ltd boosted its stake in shares of Pfizer by 8.5% during the 3rd quarter. ICICI Prudential Asset Management Co Ltd now owns 337,963 shares of the biopharmaceutical company's stock valued at $9,781,000 after buying an additional 26,500 shares during the period. Finally, Oppenheimer & Co. Inc. raised its holdings in shares of Pfizer by 8.8% during the third quarter. Oppenheimer & Co. Inc. now owns 658,388 shares of the biopharmaceutical company's stock worth $19,054,000 after acquiring an additional 53,526 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company's stock.

Analysts Set New Price Targets

Several brokerages have weighed in on PFE. Evercore ISI raised Pfizer to a "strong-buy" rating in a research report on Wednesday, October 30th. Daiwa America raised shares of Pfizer from a "moderate buy" rating to a "strong-buy" rating in a research report on Wednesday, August 7th. Daiwa Capital Markets raised shares of Pfizer from a "neutral" rating to an "outperform" rating and boosted their target price for the stock from $28.00 to $34.00 in a research report on Wednesday, August 7th. StockNews.com upgraded shares of Pfizer from a "buy" rating to a "strong-buy" rating in a research note on Tuesday. Finally, Barclays lifted their price objective on shares of Pfizer from $30.00 to $32.00 and gave the company an "equal weight" rating in a research note on Wednesday, July 31st. Eight equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat, Pfizer currently has a consensus rating of "Moderate Buy" and a consensus target price of $33.58.

Insiders Place Their Bets

In other news, Director Scott Gottlieb acquired 1,000 shares of the firm's stock in a transaction on Wednesday, October 30th. The shares were purchased at an average cost of $28.24 per share, with a total value of $28,240.00. Following the completion of the purchase, the director now owns 10,000 shares of the company's stock, valued at $282,400. This represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 0.06% of the company's stock.

Pfizer Stock Performance

Pfizer stock traded down $0.17 during trading hours on Thursday, hitting $26.55. The stock had a trading volume of 17,488,532 shares, compared to its average volume of 37,680,570. Pfizer Inc. has a fifty-two week low of $25.20 and a fifty-two week high of $31.54. The company has a market cap of $150.46 billion, a PE ratio of 35.74, a price-to-earnings-growth ratio of 0.83 and a beta of 0.67. The company has a 50-day moving average of $28.76 and a two-hundred day moving average of $28.67. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, topping analysts' consensus estimates of $0.64 by $0.42. The firm had revenue of $17.70 billion for the quarter, compared to the consensus estimate of $14.92 billion. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The business's revenue was up 31.2% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.17) earnings per share. On average, equities research analysts anticipate that Pfizer Inc. will post 2.96 EPS for the current fiscal year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, December 2nd. Shareholders of record on Friday, November 8th will be given a $0.42 dividend. This represents a $1.68 dividend on an annualized basis and a yield of 6.33%. The ex-dividend date is Friday, November 8th. Pfizer's dividend payout ratio (DPR) is 227.03%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.